Insider · CIK 0002045943
Kristin Abate
Files at KPTI (Karyopharm Therapeutics Inc.). First filing Mar 6, 2025, latest Oct 2, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KPTI: Karyopharm Therapeutics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | KPTIsell Karyopharm Therapeutics Inc. | $450 378 shares | -2% | 0% from low-92% from high | |
| 15Weak | KPTIsell Karyopharm Therapeutics Inc. | $38 19 shares | -0% | - | |
| 15Weak | KPTIsell Karyopharm Therapeutics Inc. | $504 53 shares | -0% | +136% from low-12% from high | |
| 30Weak | Karyopharm Therapeutics Inc. | $5,260 559 shares | -2% | +171% from low-5% from high | |
| 23Weak | Karyopharm Therapeutics Inc. | $352 50 shares | -0% | +95% from low-32% from high | |
| 23Weak | Karyopharm Therapeutics Inc. | $1,579 265 shares | -1% | +79% from low-40% from high | |
| 15Weak | KPTIsell Karyopharm Therapeutics Inc. | $2,279 362 shares | -3% | +75% from low-58% from high | |
| 30Weak | Karyopharm Therapeutics Inc. | $148 23 shares | -0% | +77% from low-58% from high | |
| 30Weak | Karyopharm Therapeutics Inc. | $81 12 shares | -0% | +100% from low-52% from high | |
| 23Weak | Karyopharm Therapeutics Inc. | $952 238 shares | -2% | +10% from low-74% from high | |
| 30Weak | Karyopharm Therapeutics Inc. | $3,592 571 shares | -6% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -378 | $1.19 | $450 | 23,404 | 10 d ago |
| Sep 1, 2026 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -19 | $2.02 | $38 | 23,782 | 40 d ago |
| May 13, 2026 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Common Stock | +121 | $0.00 | $0 | 23,854 | May 15, 2026 |
| May 14, 2026 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -53 | $9.50 | $504 | 23,801 | May 15, 2026 |
| Mar 2, 2026 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -559 | $9.41 | $5,260 | 22,063 | Mar 3, 2026 |
| Jan 27, 2026 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Common Stock | +92 | $0.00 | $0 | 22,672 | Jan 29, 2026 |
| Jan 28, 2026 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -50 | $7.03 | $352 | 22,622 | Jan 29, 2026 |
| Jan 21, 2026 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -265 | $5.96 | $1,579 | 22,580 | Jan 22, 2026 |
| Oct 15, 2025 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Common Stock | +12,799 | $0.00 | $0 | 22,845 | Oct 16, 2025 |
| Oct 1, 2025 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -362 | $6.30 | $2,279 | 10,046 | Oct 3, 2025 |
| Sep 12, 2025 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Common Stock | +46 | $0.00 | $0 | 10,431 | Sep 16, 2025 |
| Sep 15, 2025 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -23 | $6.43 | $148 | 10,408 | Sep 16, 2025 |
| Sep 3, 2025 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -12 | $6.78 | $81 | 9,463 | Sep 4, 2025 |
| Jul 22, 2025 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -238 | $4.00 | $952 | 9,475 | Jul 23, 2025 |
| Mar 4, 2025 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -571 | $6.29 | $3,592 | 9,713 | Mar 6, 2025 |
| Feb 28, 2025 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Common Stock | +933 | $0.00 | $0 | 10,284 | Mar 4, 2025 |
| Feb 28, 2025 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +1,866 | $0.00 | $0 | 1,866 | Mar 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.